Caprolactam Chemicals Ltd

Caprolactam Chemicals Ltd (CAPRO) is a micro-cap Chemicals company valued at ₹22 crore operating in Commodity Chemicals on the NSE and BSE.

Recent price move

Caprolactam Chemicals Ltd last traded at ₹47.48, unchanged on the day.

Recent developments

On 2026-06-30, the company reported a revenue of ₹0 crore and a net loss of ₹1 crore for the latest quarter, marking a sharp decline from the previous year's quarter, which had revenue of ₹3 crore and a net profit of ₹0 crore. The company's promoter holding remained at 54.50% as of 2026-09-30, with no foreign or domestic institutional holdings reported.

Financial performance

The company's annual revenue rose 56.7% year-over-year, but the latest quarter saw a sharp drop of 81.6% compared to the same quarter a year earlier. Net profit swung from a loss of ₹1 crore to a profit of ₹2 crore annually, but the latest quarter reported a loss of ₹1 crore, down from a profit of ₹0 crore in the same quarter last year. The net profit margin improved significantly, rising 27.2 percentage points to 16.7%, while return on equity and return on capital employed remained stable at 26.8% and 18.2%, respectively.

Valuation multiples

The stock trades at 12.4 times earnings, 3.27 times book value.

Things to watch

The latest quarter's revenue fell 81.6% compared to the same quarter a year earlier, and the company reported a net loss of ₹1 crore, down from a profit of ₹0 crore in the same period last year. The stock is 41.4% below its 52-week high, and the company's profit growth over the past five years has slowed, with a 22.0% annualized increase, but the three-year profit growth has declined by 11.6% annually.

Where it stands

Caprolactam Chemicals Ltd ended the latest quarter with a net loss of ₹1 crore, down from a profit of ₹0 crore in the same quarter last year, while annual net profit swung from a loss to a profit. The stock is 41.4% below its 52-week high, and the company's profit growth has slowed in recent years. The most significant movement was the sharp decline in revenue and net profit in the latest quarter.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.